<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Preparations for menopausal hormone therapy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Preparations for menopausal hormone therapy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Preparations for menopausal hormone therapy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Martin, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert L Barbieri, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Snyder, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William F Crowley, Jr, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jean E Mulder, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 18, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Menopausal hormone therapy (MHT) is commonly used to treat vasomotor symptoms and genitourinary syndrome of menopause (GSM). The benefits of MHT outweigh the risk for healthy, symptomatic women who are within 10 years of menopause or younger than age 60 years and who do not have contraindications to MHT (such as a history of breast cancer, coronary heart disease [CHD], a previous venous thromboembolic event or stroke, or active liver disease).</p><p>This topic will review the available estrogen and progestin preparations, as well as other types of hormone preparations. An overview of the risks and benefits of MHT, treatment of menopausal symptoms with MHT (including choice of therapy), complementary and nonhormonal treatment options, and the use of estrogen in women with early menopause (primary ovarian insufficiency [POI]) are reviewed separately. (See  <a class="medical medical_review" href="/d/html/7427.html" rel="external">"Menopausal hormone therapy: Benefits and risks"</a> and  <a class="medical medical_review" href="/d/html/7450.html" rel="external">"Treatment of menopausal symptoms with hormone therapy"</a> and  <a class="medical medical_review" href="/d/html/7390.html" rel="external">"Menopausal hot flashes"</a> and  <a class="medical medical_review" href="/d/html/7426.html" rel="external">"Management of primary ovarian insufficiency (premature ovarian failure)", section on 'Importance of estrogen therapy'</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">ESTROGEN PREPARATIONS</span><span class="headingEndMark"> — </span>Estrogen is available in many forms: oral, transdermal, topical gels, emulsions and lotions, intravaginal creams and tablets, and vaginal rings. In some countries, estrogen can also be given as a subcutaneous implant  (<a class="graphic graphic_table graphicRef78136" href="/d/graphic/78136.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]. Once a decision has been made to treat a woman with menopausal hormone therapy (MHT), consideration should be given to the type of estrogen and the route by which it is to be given, as well as the need for progestin and the most appropriate progestin regimen (see <a class="local">'Progestin preparations'</a> below). Estrogen doses used for women who have menopausal symptoms are typically lower than doses used to treat women with primary ovarian insufficiency (POI). (See  <a class="medical medical_review" href="/d/html/7426.html" rel="external">"Management of primary ovarian insufficiency (premature ovarian failure)", section on 'Importance of estrogen therapy'</a>.)</p><p>Women being treated for menopausal symptoms such as hot flashes require systemic estrogen; women being treated only for vulvovaginal atrophy (now referred to as "genitourinary syndrome of menopause" [GSM]) should be treated with low-dose vaginal estrogen rather than systemic estrogen. (See  <a class="medical medical_review" href="/d/html/7450.html" rel="external">"Treatment of menopausal symptoms with hormone therapy"</a> and  <a class="medical medical_review" href="/d/html/5443.html" rel="external">"Genitourinary syndrome of menopause (vulvovaginal atrophy): Treatment"</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Systemic estrogens</span><span class="headingEndMark"> — </span>Systemic estrogen is most often administered orally or transdermally  (<a class="graphic graphic_table graphicRef78136" href="/d/graphic/78136.html" rel="external">table 1</a>). One vaginal ring containing an estrogen dose high enough to treat hot flashes is also available [<a href="#rid2">2</a>]. Other vaginal estrogens are low-dose preparations used for genitourinary syndrome of menopause (see <a class="local">'High dose (systemic estrogen)'</a> below and <a class="local">'Low dose'</a> below). There are several important differences between transdermal and oral preparations:</p><p class="bulletIndent1"><span class="glyph">●</span>Estrogens administered orally, but not transdermally, undergo hepatic metabolism, the "first-pass effect." The high portal vein estrogen concentrations seen with oral administration increases the hepatic production of most proteins produced by the liver, including thyroxine-binding globulin (TBG), corticosteroid-binding globulin (CBG), sex hormone-binding globulin (SHBG), triglycerides, high-density lipoprotein (HDL) cholesterol, and clotting factors, whereas their production is only minimally increased by transdermal estrogen administration [<a href="#rid3">3,4</a>]. Furthermore, the saturation of bile with cholesterol is adversely affected by oral, but not transdermal, estrogen [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All estrogens are effective for managing menopausal symptoms such as hot flashes. Transdermal estrogen is as effective as oral estrogen for preserving bone density  (<a class="graphic graphic_figure graphicRef51848" href="/d/graphic/51848.html" rel="external">figure 1</a>) [<a href="#rid6">6</a>]. Transdermal estrogen administration is associated with a lower risk of venous thrombosis and stroke, and it has less of an effect on serum lipid concentrations when compared with a comparable dose of oral estrogen [<a href="#rid3">3,4,7</a>]. (See <a class="local">'Transdermal estrogen'</a> below and  <a class="medical medical_review" href="/d/html/7409.html" rel="external">"Menopausal hormone therapy and cardiovascular risk", section on 'Lipids'</a> and  <a class="medical medical_review" href="/d/html/7409.html" rel="external">"Menopausal hormone therapy and cardiovascular risk", section on 'Venous thromboembolism'</a>.)</p><p></p><p class="headingAnchor" id="H4"><span class="h3">Oral estrogen</span><span class="headingEndMark"> — </span>A number of oral estrogen preparations are available  (<a class="graphic graphic_table graphicRef78136" href="/d/graphic/78136.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Oral micronized 17-beta <a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a> is structurally identical (bioidentical) to the main product of the premenopausal ovary. Oral 17-beta estradiol is poorly absorbed unless it is micronized, in which case it is absorbed through the lymphatic system. Therefore, all commercially available oral 17-beta estradiol products are micronized.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9424" href="/d/drug information/9424.html" rel="external">Conjugated equine estrogens</a> (CEEs) are comprised mostly of <a class="drug drug_general" data-topicid="107870" href="/d/drug information/107870.html" rel="external">estrone</a> sulfate with small amounts of equilin sulfate, dihydroequilin sulfate, and many other estrogens [<a href="#rid1">1</a>] and are derived from pregnant mares' urine. In order for estrogens to appear in the urine, they must undergo conjugation to become more polar and soluble in water.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9425" href="/d/drug information/9425.html" rel="external">Esterified estrogens</a>, which result in serum <a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a> and <a class="drug drug_general" data-topicid="107870" href="/d/drug information/107870.html" rel="external">estrone</a> levels that are comparable with those seen with conjugated estrogen [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Estropipate, a salt of <a class="drug drug_general" data-topicid="107870" href="/d/drug information/107870.html" rel="external">estrone</a> sulfate and piperazine.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ethinyl <a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a>, the estrogen used in almost all oral contraceptive preparations. Ethinyl estradiol is much more potent than the other estrogens used for MHT and, therefore, is used in very low doses (5 mcg). Ethinyl estradiol is used in at least one combined estrogen-progestin product that contains 2.5 to 5 mcg of ethinyl estradiol with 0.5 or 1 mg <a class="drug drug_general" data-topicid="10173" href="/d/drug information/10173.html" rel="external">norethindrone</a> acetate, respectively  (<a class="graphic graphic_table graphicRef78136" href="/d/graphic/78136.html" rel="external">table 1</a>).</p><p></p><p class="headingAnchor" id="H3990570885"><span class="h4">Source</span><span class="headingEndMark"> — </span>Most oral estrogen preparations, with the exception of CEEs, are derived from plant sources. There is no evidence that plant-derived estrogens have any safety and efficacy advantages over those derived from pregnant mare urine (eg, CEE). However, in our experience, many women prefer the plant-derived estrogens.</p><p class="headingAnchor" id="H1720165020"><span class="h4">Efficacy/potency</span><span class="headingEndMark"> — </span>The different oral estrogens have similar efficacy. Conjugated estrogen and <a class="drug drug_general" data-topicid="107870" href="/d/drug information/107870.html" rel="external">estrone</a> sulfate are absorbed from the gastrointestinal tract primarily as estrone sulfate, which is biologically inactive [<a href="#rid9">9</a>]. Oral <a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a> is converted to estrone and then estrone sulfate in liver and other tissues. In women taking oral estradiol, circulating estrone sulfate accumulates as a large precursor pool. The estrone sulfate is then continuously desulfated and converted to estradiol. Therefore, even though oral estrogen is administered in a single daily dose, the resulting serum estradiol concentrations vary little between doses [<a href="#rid10">10</a>].</p><p>The potency, and therefore the doses, of these estrogen preparations differ, but they differ little in efficacy [<a href="#rid10">10</a>]. In general, 0.625 mg of conjugated estrogens or esterified estrogen is considered equivalent to 1 mg of micronized 17-beta <a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a>, 0.05 mg of transdermal estradiol, or 5 mcg of ethinyl estradiol  (<a class="graphic graphic_table graphicRef78136" href="/d/graphic/78136.html" rel="external">table 1</a>). (See <a class="local">'Dose equivalents'</a> below.)</p><p>These doses protect bone and relieve vasomotor symptoms in most women. Lower doses are effective for vasomotor symptoms in many women; most experts recommend starting with low-dose estrogen unless the patient has severe symptoms. The dose can be titrated up if symptoms are not completely relieved by the low dose of estrogen. (See <a class="local">'Dosing'</a> below.)</p><p class="headingAnchor" id="H6"><span class="h3">Transdermal estrogen</span><span class="headingEndMark"> — </span>There are many transdermal estrogen preparations available that contain 17-beta <a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a> with a wide range of dosing options, from 0.014 to 0.1 mg/day (ie, 14 to 100 mcg/day). A transdermal dose of 0.05 mg/day [<a href="#rid6">6</a>] is approximately equivalent to 1 mg of oral 17-beta estradiol and a 0.625 mg daily oral dose of conjugated estrogens [<a href="#rid1">1</a>]. The package labeling for transdermal estrogens expresses doses in "mg" rather than "mcg" (eg, 0.014, 0.05, 0.1 mg).</p><p>The lowest-dose patch containing 0.014 mg of 17-beta <a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a> is approved for prevention of osteoporosis. In some women, that dose is also adequate for relief of hot flashes in some women [<a href="#rid11">11,12</a>]. For women with a uterus, addition of a progestin is recommended, although the optimal interval for its administration is not known. For this low-dose patch (0.014 mg), many clinicians administer a 14-day cycle of oral progestin every 6 to 12 months as suggested by the US Food and Drug Administration (FDA), although this has not been well studied.</p><p class="headingAnchor" id="H533430863"><span class="h3">Topical estradiol</span><span class="headingEndMark"> — </span>A wide range of topical <a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a> preparations are commercially available, all of which are effective for the treatment of vasomotor symptoms. The preparations available in the United States include the following  (<a class="graphic graphic_table graphicRef78136" href="/d/graphic/78136.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>A lotion-like emulsion that is applied to the thighs or calves of each leg (foil packets, one packet per leg, total dose of 3.48 g/day, which delivers 0.05 mg <a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a>/day) [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are several gels available:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>One gel is packaged in a non-aerosol, metered-dose pump and is applied once daily on one arm (from wrist to shoulder). The recommended daily dose is 1.25 g, which delivers 0.75 mg <a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a>/day [<a href="#rid14">14</a>]. In one trial of 221 postmenopausal women with vasomotor flushes, a significant decrease in the frequency of flushes was seen with this dose when compared with placebo [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A second gel is supplied in foil packets and is available in three doses: 0.25, 0.50, and 1.0 mg of <a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a> [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A third gel is administered via a pump in two doses (0.87 g, which contains 0.52 mg of <a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a>, and 1.7 g, which contains approximately 1 mg of estradiol) [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lastly, a topical skin spray is available that delivers 1.53 mg of <a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a> with each spray [<a href="#rid18">18,19</a>].</p><p></p><p>The topical estrogen spray preparation has been associated with adverse effects in children and pets who were exposed to the drug via skin contact [<a href="#rid20">20</a>]. The drug is sprayed on the skin between the elbow and wrist, on the inside of the forearm. Eight cases of unintended exposure have been reported in children ages 3 to 5 years. Adverse events have included nipple swelling and breast development in girls and breast enlargement in boys, occurring weeks to months after the drug was initiated in the adult. In some cases, the effects were reversible after the estrogen spray was discontinued.</p><p>Adverse events in pets exposed to the topical spray (mammary/nipple enlargement and vulvar swelling) have also been reported.</p><p class="headingAnchor" id="H2236117046"><span class="h3">Dosing</span><span class="headingEndMark"> — </span>Low-dose estrogen is effective for hot flashes in many women and is associated with fewer side effects. (See  <a class="medical medical_review" href="/d/html/7427.html" rel="external">"Menopausal hormone therapy: Benefits and risks"</a> and  <a class="medical medical_review" href="/d/html/7450.html" rel="external">"Treatment of menopausal symptoms with hormone therapy", section on 'Dose'</a>.)</p><p>"Ultra-low doses" of estrogen (transdermal <a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a> 0.014 mg/day and oral micronized 17-beta estradiol 0.25 mg/day) also appear to prevent bone loss [<a href="#rid11">11,21</a>] and are effective for hot flashes in some women. (See <a class="local">'Transdermal estrogen'</a> above and  <a class="medical medical_review" href="/d/html/7428.html" rel="external">"Menopausal hormone therapy in the prevention and treatment of osteoporosis"</a>.)</p><p class="headingAnchor" id="H2708903772"><span class="h4">Dose equivalents</span><span class="headingEndMark"> — </span>Many studies of the safety and efficacy of postmenopausal estrogen have used conjugated estrogen 0.625 mg. This is considered to be standard-dose estrogen; low-dose preparations, in general, contain one-half the standard dose. The doses of other estrogens that are similarly effective for the treatment of hot flashes as 0.625 mg of CEE include  (<a class="graphic graphic_table graphicRef78136" href="/d/graphic/78136.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>1 mg micronized 17-beta <a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>0.05 mg/day transdermal 17-beta <a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>1.25 mg piperazine <a class="drug drug_general" data-topicid="107870" href="/d/drug information/107870.html" rel="external">estrone</a> sulfate</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">Estradiol</a> gels and sprays are available in different strengths and delivery systems (pump, foil packets). Dosing equivalents depend upon the individual preparation. Measurement of estradiol levels may be warranted when trying to adjust dosing.</p><p></p><p class="headingAnchor" id="H352147104"><span class="h2">Vaginal estrogen</span></p><p class="headingAnchor" id="H2752681372"><span class="h3">High dose (systemic estrogen)</span><span class="headingEndMark"> — </span><strong>Higher</strong> doses of vaginal estrogen can be used to treat vasomotor symptoms, much like any of the preparations for systemic use [<a href="#rid22">22</a>]. As an example, a vaginal ring is available in two doses, releasing 0.05 mg/day or 0.1 mg/day over three months. A progestin needs to be added for women with a uterus. We do <strong>not </strong>recommend these higher vaginal estrogen doses (ie, systemic estrogen doses) in women who need therapy for genitourinary symptoms only  (<a class="graphic graphic_table graphicRef78136" href="/d/graphic/78136.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H1282457458"><span class="h3">Low dose</span><span class="headingEndMark"> — </span>Vaginal estrogen is most commonly used in very <strong>low</strong> doses for the management of vaginal atrophy (now known as GSM). These low-dose vaginal preparations are not associated with cardiovascular or oncologic complications. The absorption of estrogen from the vagina and its efficacy for GSM is reviewed separately. (See  <a class="medical medical_review" href="/d/html/5443.html" rel="external">"Genitourinary syndrome of menopause (vulvovaginal atrophy): Treatment", section on 'Vaginal estrogen therapy'</a>.)</p><p class="headingAnchor" id="H2245443123"><span class="h2">Not recommended</span></p><p class="headingAnchor" id="H4141746366"><span class="h3">Depot estrogen</span><span class="headingEndMark"> — </span>Estrogen is also available in some, but not all, countries as long-acting (three to four weeks) injections of either <a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a> cypionate or estradiol valerate. Given the other effective estrogen options, we do not use this approach  (<a class="graphic graphic_table graphicRef78136" href="/d/graphic/78136.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H10327899"><span class="h3">Compounded bioidentical hormone therapy</span><span class="headingEndMark"> — </span>The term "bioidentical hormone" technically refers to a hormone with the same molecular structure as a hormone that is endogenously produced (eg, 17-beta <a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a>). However, in popular culture, the term refers to the use of custom-compounded, multihormone regimens with dose adjustments based upon serial hormone monitoring.</p><p>Many postmenopausal women are turning to this approach because of safety concerns about conventional hormone preparations. However, we agree with a number of expert groups, including the North American Menopause Society, American College of Obstetricians and Gynecologists, and Endocrine Society, all of whom advise against the use of custom-compounded hormones, most importantly because of the lack of stringent quality controls regarding purity and dosing [<a href="#rid23">23-25</a>]. This issue is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7450.html" rel="external">"Treatment of menopausal symptoms with hormone therapy", section on 'Compounded bioidentical hormone therapy'</a>.)</p><p class="headingAnchor" id="H1093201141"><span class="h4">Misleading terminology</span><span class="headingEndMark"> — </span>Some of the terms used by this industry to describe hormone preparations can be confusing and misleading. Examples include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bioidentical hormones</strong> – The term "bioidentical hormone" technically refers to a hormone with the same molecular structure as a hormone that is endogenously produced (eg, 17-beta <a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a>, a hormone produced by the ovary). However, in popular culture, the term now typically refers to the use of custom-compounded, multihormone regimens with dose adjustments based upon serial hormone monitoring. Most expert groups advise against this approach. (See <a class="local">'Compounded bioidentical hormone therapy'</a> above and  <a class="medical medical_review" href="/d/html/7450.html" rel="external">"Treatment of menopausal symptoms with hormone therapy", section on 'Compounded bioidentical hormone therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Natural versus synthetic</strong> – This term "natural" is often used to refer to estrogens that are derived from plant sources. With the exception of CEEs that are derived from urine of pregnant mares, virtually all estrogens used for MHT are derived from plant sources. However, these same estrogens can also be considered "synthetic" because the plant precursors must be extracted and converted to the desired estrogen through a multistep process. For example, 17-beta <a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a> is synthesized from diosgenin, a compound naturally occurring in plants (Mexican <em>Dioscorea </em>species). Diosgenin is then converted to <a class="drug drug_general" data-topicid="107870" href="/d/drug information/107870.html" rel="external">estrone</a> and hydrogenated to 17-beta estradiol [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1">The custom-compounded bioidentical industry claims that their products are "natural" and "plant-derived," and that commercially available estrogens that are regulated and approved in most countries are synthetic and not "plant-based." In fact, all of the hormones used for their products are synthesized using the same process as described above for regulated and approved hormones, ie, precursors are extracted from plant sources, and the plant precursor is then converted to estrogen in the lab. However, quality controls for these processes vary widely in terms of their quality controls.</p><p></p><p class="headingAnchor" id="H17"><span class="h1">PROGESTIN PREPARATIONS</span><span class="headingEndMark"> — </span>Endometrial hyperplasia and cancer can occur after as little as six months of unopposed estrogen therapy; as a result, a progestin should be added in women who have not had a hysterectomy. Women who have undergone hysterectomy should not receive a progestin. All of the progestin regimens described below are effective for the prevention of endometrial cancer, whether oral or transdermal estrogen is used [<a href="#rid27">27</a>]. Available progestin preparations are reviewed here. (See  <a class="medical medical_review" href="/d/html/7427.html" rel="external">"Menopausal hormone therapy: Benefits and risks", section on 'Endometrial hyperplasia and carcinoma'</a>.)</p><p class="headingAnchor" id="H469477597"><span class="h2">Micronized progesterone</span><span class="headingEndMark"> — </span>Natural oral micronized <a class="drug drug_general" data-topicid="9817" href="/d/drug information/9817.html" rel="external">progesterone</a> is structurally identical (bioidentical) to the progesterone secreted by the human ovary. Most experts now prefer micronized progesterone (MP) over <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> (MPA), the synthetic progestin most commonly used in the past, as it has a number of advantages. Both progestins are effective for endometrial protection, but unlike MPA, which has been associated with an excess risk of cardiovascular events and breast cancer, MP is metabolically neutral (ie, does not negate the beneficial effects of estrogens on lipids) and does not appear to increase the risk of either breast cancer or cardiovascular disease, although data are limited [<a href="#rid28">28-32</a>]. (See  <a class="medical medical_review" href="/d/html/7409.html" rel="external">"Menopausal hormone therapy and cardiovascular risk", section on 'Effects of progestins'</a> and  <a class="medical medical_review" href="/d/html/7392.html" rel="external">"Menopausal hormone therapy and the risk of breast cancer", section on 'Type of progestin'</a> and  <a class="medical medical_review" href="/d/html/7450.html" rel="external">"Treatment of menopausal symptoms with hormone therapy", section on 'Compounded bioidentical hormone therapy'</a>.)</p><p>The usual dose is 200 mg/day cyclically or 100 mg/day continuously; 200 mg/day for 12 days is the most carefully studied dose [<a href="#rid29">29,32-34</a>].</p><p>Although small studies of intravaginal <a class="drug drug_general" data-topicid="9817" href="/d/drug information/9817.html" rel="external">progesterone</a> suggest that it might be a useful alternative for menopausal women taking estrogen who cannot tolerate oral progestins [<a href="#rid35">35,36</a>], additional data are needed before recommending this approach.</p><p class="headingAnchor" id="H19"><span class="h2">Medroxyprogesterone acetate</span><span class="headingEndMark"> — </span>The most commonly prescribed synthetic progestin historically has been MPA, given in a cyclic (5 to 10 mg/day) or continuous (1.25 to 2.5 mg/day) regimen. Most studies of the efficacy of progestins, including the Women's Health Initiative (WHI), have used this compound. Although MPA has proven efficacy for preventing endometrial hyperplasia, it appears to be associated with an excess risk of breast cancer and possibly coronary heart disease (CHD). In addition, it has unfavorable effects on lipids. (See  <a class="medical medical_review" href="/d/html/7409.html" rel="external">"Menopausal hormone therapy and cardiovascular risk", section on 'Effects of progestins'</a> and  <a class="medical medical_review" href="/d/html/7392.html" rel="external">"Menopausal hormone therapy and the risk of breast cancer", section on 'Type of progestin'</a> and  <a class="medical medical_review" href="/d/html/7409.html" rel="external">"Menopausal hormone therapy and cardiovascular risk", section on 'Lipids'</a>.)</p><p class="headingAnchor" id="H100236022"><span class="h2">Intolerance to progestins</span><span class="headingEndMark"> — </span>Many women have difficulty tolerating progestins, most commonly because of adverse effects on mood. There are some alternative options, but all need require further study before recommending them for routine use. (See  <a class="medical medical_review" href="/d/html/7450.html" rel="external">"Treatment of menopausal symptoms with hormone therapy", section on 'Side effects'</a>.)</p><p class="headingAnchor" id="H23"><span class="h3">Levonorgestrel-releasing intrauterine device</span><span class="headingEndMark"> — </span>Levonorgestrel-releasing intrauterine systems (LNG-IUS) are contraceptive agents that are also effective and approved in some countries for endometrial protection for menopausal women taking estrogen [<a href="#rid37">37</a>]. They are not approved for this indication in the United States, but many clinicians have used them off-label for women who cannot tolerate oral progestins.</p><p>We will consider switching to an LNG-IUS if they are unable to tolerate oral progestins and we anticipate that they will be on estrogen for at least another three years (the lower-dose LNG-IUS is approved for up to three years of use) [<a href="#rid38">38</a>]. LNG-IUS provide very high intrauterine but low systemic concentrations of <a class="drug drug_general" data-topicid="104542" href="/d/drug information/104542.html" rel="external">levonorgestrel</a>; almost all women develop a nonproliferative, atrophic endometrium. LNG-IUS are also an attractive option for perimenopausal women who either need contraception, are having heavy bleeding, or both.</p><p>Two meta-analyses of trials in women using LNG-20 combined with estrogen therapy reported that the intrauterine device (IUD) was as good [<a href="#rid39">39</a>] or better [<a href="#rid40">40</a>] than estrogen combined with systemic progestins for preventing endometrial hyperplasia. Data for LNG-14 are more limited, but in a study of 150 peri- and postmenopausal women using the LNG-14 in addition to transdermal <a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a>, no cases of endometrial hyperplasia were seen [<a href="#rid41">41</a>]. However, only 101 (67 percent) of the 150 women underwent endometrial biopsy. In a second study, among 102 women who used two consecutive systems (LNG-14 for the first three years, after which LNG-20 was inserted), endometrial biopsies showed atrophy in all but two women; theirs showed weak proliferation [<a href="#rid42">42</a>]. There were no cases of hyperplasia.</p><p>An observational study in Finland reported that when LNG-IUS was used for protection against endometrial hyperplasia in menopausal women, there was an increased risk of breast cancer whether or not the women were taking <a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a>. The study may not have controlled for risk factors for postmenopausal breast cancer such as obesity [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H1514264817"><span class="h3">Quarterly progestin regimens</span><span class="headingEndMark"> — </span>Quarterly progestin regimens are probably not adequate for endometrial protection, and we suggest against this approach. Administration of MPA for 14 days every 3 months has been investigated as a strategy for women who have difficulty tolerating progestin therapy [<a href="#rid44">44,45</a>]. However, these regimens may be associated with higher than normal rates of endometrial hyperplasia [<a href="#rid46">46</a>]. With increasing concerns about the role of progestin exposure on the risk of breast cancer, there is renewed interest in these types of regimens, particularly with the increasing use of lower doses of estrogens. However, data are not yet available on quarterly progestin regimens for low-dose estrogen.</p><p class="headingAnchor" id="H1164051542"><span class="h3">Tissue selective estrogen complexes (TSECs)</span><span class="headingEndMark"> — </span>TSECs refers to the combination of a selective estrogen receptor modulator (SERM) and an estrogen. The combination of bazedoxifene, a SERM, and conjugated estrogen<em> </em>is available in the United States for the treatment of menopausal vasomotor symptoms and osteoporosis prevention. Its role in the management of women who cannot tolerate progestin therapy remains unclear, and we do not suggest its routine use.</p><p>The SERM bazedoxifene prevents estrogen-induced endometrial hyperplasia so that administering a progestin is not necessary in women with a uterus. It may be useful for women with moderate to severe hot flashes who have breast tenderness with standard estrogen-progestin therapy or for women who cannot tolerate any type of progestin therapy because of side effects. Like other SERMs, bazedoxifene is associated with increased risk of venous thromboembolic events. The role of combination conjugated estrogen-bazedoxifene for menopausal symptoms and bone loss is reviewed in more detail separately. (See  <a class="medical medical_review" href="/d/html/7390.html" rel="external">"Menopausal hot flashes", section on 'Bazedoxifene/conjugated estrogen'</a> and  <a class="medical medical_review" href="/d/html/2068.html" rel="external">"Selective estrogen receptor modulators for prevention and treatment of osteoporosis", section on 'Bazedoxifene-conjugated estrogen'</a>.)</p><p class="headingAnchor" id="H1130129907"><span class="h1">COMBINATION ESTROGEN-PROGESTIN PRODUCTS</span></p><p class="headingAnchor" id="H3474542411"><span class="h2">Oral</span><span class="headingEndMark"> — </span>Although many postmenopausal women in the United States receive oral <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> (MPA) or micronized <a class="drug drug_general" data-topicid="9817" href="/d/drug information/9817.html" rel="external">progesterone</a> (MP), there are combination preparations that contain other progestins derived from <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> (19-nortestestosterone), such as <a class="drug drug_general" data-topicid="10173" href="/d/drug information/10173.html" rel="external">norethindrone</a> acetate and norgestimate, and the 17-alpha <a class="drug drug_general" data-topicid="9943" href="/d/drug information/9943.html" rel="external">spironolactone</a> derivative <a class="drug drug_general" data-topicid="121397" href="/d/drug information/121397.html" rel="external">drospirenone</a>  (<a class="graphic graphic_table graphicRef78136" href="/d/graphic/78136.html" rel="external">table 1</a>).</p><p>In a trial of 1142 postmenopausal women randomly assigned to receive oral <a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a> alone (1 mg/day) or in combination with <a class="drug drug_general" data-topicid="121397" href="/d/drug information/121397.html" rel="external">drospirenone</a> 0.5, 1, 2, or 3 mg/day for 13 months, all of the combination <a class="drug drug_general" data-topicid="8802" href="/d/drug information/8802.html" rel="external">drospirenone-estradiol</a> regimens decreased the risk of endometrial hyperplasia when compared with unopposed estrogen [<a href="#rid47">47</a>]. Hyperkalemia was not observed in any patient, and favorable changes in lipids were noted in all of the drospirenone-estradiol groups (decreases in serum total cholesterol, triglycerides, and low-density lipoprotein [LDL] cholesterol concentrations and increases in serum high-density lipoprotein [HDL] when compared with baseline).</p><p>Menopausal women with severe symptoms who plan to take hormone therapy typically prefer regimens that (1) contain "bioidentical" hormones, (2) are easy to use, and (3) will not result in weight gain or other adverse effects. An oral capsule containing 1 mg 17-beta-estradiol (E2) combined with 100 mg MP (both bioidentical) is effective and approved for the treatment of hot flashes; it is also endometrial protective [<a href="#rid48">48,49</a>]. In a one-year trial of the oral E2/MP capsule versus placebo, the combined hormone therapy had no clinically meaningful effect on either weight or blood pressure when compared with placebo [<a href="#rid50">50</a>].</p><p>This preparation should provide an attractive alternative to women who are currently using compounded bioidentical hormone therapies. (See  <a class="medical medical_review" href="/d/html/7450.html" rel="external">"Treatment of menopausal symptoms with hormone therapy", section on 'Compounded bioidentical hormone therapy'</a>.)</p><p class="headingAnchor" id="H1473561493"><span class="h2">Transdermal</span><span class="headingEndMark"> — </span>Combination patches are also available. One contains 17-beta <a class="drug drug_general" data-topicid="9422" href="/d/drug information/9422.html" rel="external">estradiol</a> (0.05 mg/day) with <a class="drug drug_general" data-topicid="10173" href="/d/drug information/10173.html" rel="external">norethindrone</a> acetate (0.14 or 0.25 mg/day) applied twice weekly. This preparation appears to be comparable with other combined regimens for relief of vasomotor flushes and prevention of endometrial hyperplasia [<a href="#rid51">51</a>]. A second combination patch contains 17-beta estradiol (0.045 mg/day) with <a class="drug drug_general" data-topicid="104542" href="/d/drug information/104542.html" rel="external">levonorgestrel</a> (0.15 mg/day) and is applied once a week  (<a class="graphic graphic_table graphicRef78136" href="/d/graphic/78136.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H497591676"><span class="h1">OTHER HORMONE PREPARATIONS</span></p><p class="headingAnchor" id="H32"><span class="h2">Androgens</span><span class="headingEndMark"> — </span>Exogenous <a class="drug drug_general" data-topicid="9981" href="/d/drug information/9981.html" rel="external">testosterone</a> therapy has been shown to improve some aspects of female sexual function in carefully selected populations of postmenopausal women (eg, those who develop female sexual interest/arousal disorder after undergoing bilateral oophorectomy). Testosterone, at the doses usually used to treat hypoactive sexual desire disorder (HSDD), does not appear to have any beneficial effects on bone density, mood, cognition, or vasomotor symptoms. Testosterone preparations in doses appropriate for women have not been approved in most countries. (See  <a class="medical medical_review" href="/d/html/7447.html" rel="external">"Overview of androgen deficiency and therapy in females"</a> and  <a class="medical medical_review" href="/d/html/5485.html" rel="external">"Overview of sexual dysfunction in females: Management", section on 'Androgens'</a>.)</p><p>Androgen production, sexual function, and the role of androgen therapy after menopause are reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/7447.html" rel="external">"Overview of androgen deficiency and therapy in females"</a> and  <a class="medical medical_review" href="/d/html/5424.html" rel="external">"Overview of sexual dysfunction in females: Epidemiology, risk factors, and evaluation", section on 'Age and menopause'</a>.)</p><p class="headingAnchor" id="H533432775"><span class="h2">Tibolone</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="129317" href="/d/drug information/129317.html" rel="external">Tibolone</a>, a drug that has been widely used in Europe and other countries for many years for hot flashes, is a synthetic steroid whose metabolites have estrogenic, androgenic, and progestogenic properties. It is <strong>not</strong> available in the United States. Tibolone reduces vasomotor symptoms when compared with placebo, but it is less effective than estrogen therapy [<a href="#rid52">52</a>]. It also has a beneficial effect on bone mineral density (BMD), and it may have a modest effect for symptoms of sexual dysfunction. However, tibolone increases the risk of recurrence in women with a history of breast cancer, and it may increase the risk of stroke in women over age 60 [<a href="#rid52">52</a>]. The effects of tibolone on bone and sexual function are reviewed separately. (See  <a class="medical medical_review" href="/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women"</a> and  <a class="medical medical_review" href="/d/html/5485.html" rel="external">"Overview of sexual dysfunction in females: Management", section on 'Tibolone'</a>.)</p><p>The vascular, breast, and endometrial effects of <a class="drug drug_general" data-topicid="129317" href="/d/drug information/129317.html" rel="external">tibolone</a> include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stroke</strong> – The Long-term Intervention on Fracture with <a class="drug drug_general" data-topicid="129317" href="/d/drug information/129317.html" rel="external">Tibolone</a> (LIFT) trial, which was designed to determine the effect of tibolone on the risk of vertebral fracture in postmenopausal women (n = 4538, average 68 years), was stopped early because of an excess risk of stroke in women receiving tibolone when compared with placebo (relative risk [RR] 2.2) [<a href="#rid53">53</a>]. However, there were no significant differences in the risk of coronary heart disease (CHD) or venous thromboembolism between the two groups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mammographic density</strong> – <a class="drug drug_general" data-topicid="129317" href="/d/drug information/129317.html" rel="external">Tibolone</a> does not appear to increase mammographic density or the frequency of abnormal mammograms requiring follow-up [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of breast cancer</strong> – Data on the risk of breast cancer with <a class="drug drug_general" data-topicid="129317" href="/d/drug information/129317.html" rel="external">tibolone</a> have been conflicting. However, in a meta-analysis of four trials including 5500 women without breast cancer taking tibolone or placebo, there was no evidence of differences in breast cancer risk between the two groups (odds ratio [OR] 0.52, 95% CI 0.21-1.25) [<a href="#rid52">52</a>]. However, other data suggest there may be an increased risk [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Breast cancer recurrence</strong> – In women with a personal history of breast cancer, <a class="drug drug_general" data-topicid="129317" href="/d/drug information/129317.html" rel="external">tibolone</a> may increase the risk of recurrence [<a href="#rid52">52,56</a>]. This was illustrated in the Livial Intervention following Breast Cancer; Efficacy, Recurrence, and Tolerability Endpoints (LIBERATE) trial, which was designed to compare the efficacy and safety of tibolone versus placebo for vasomotor symptoms in 3148 breast cancer survivors who were randomly assigned to receive tibolone 2.5 mg or placebo [<a href="#rid56">56</a>]. After a mean follow-up of three years, 237 of 1556 women on tibolone (15 percent) had a breast cancer recurrence, compared with 138 of 1213 (11.4 percent) in the placebo group (hazard ratio [HR] 1.40, 95% CI 1.16-1.79).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaginal bleeding and endometrial hyperplasia</strong> – While some women have vaginal bleeding with <a class="drug drug_general" data-topicid="129317" href="/d/drug information/129317.html" rel="external">tibolone</a> [<a href="#rid57">57,58</a>], the rate of unscheduled bleeding is lower than that for menopausal hormone therapy (MHT) [<a href="#rid52">52,59</a>], and many develop amenorrhea. In the LIFT trial, vaginal bleeding occurred in nearly 10 percent of women taking tibolone, significantly more than the 3 percent taking placebo [<a href="#rid53">53</a>]. However, tibolone had a better bleeding profile than combined continuous estrogen-progestin therapy in the Tibolone Histology of the Endometrium and Breast Endpoints Study (THEBES); amenorrhea was reported more often in the tibolone group (71 to 78 percent) than in the hormone therapy group (45 percent) [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent1">The risk of endometrial hyperplasia does not appear to be increased with <a class="drug drug_general" data-topicid="129317" href="/d/drug information/129317.html" rel="external">tibolone</a>, although data are conflicting. The Million Women Study, an observational study, reported an increased risk of endometrial hyperplasia with tibolone [<a href="#rid60">60</a>]. However, results from the THEBES trial described above (a randomized clinical trial of 3240 women) did not confirm this [<a href="#rid59">59</a>]. (See  <a class="medical medical_review" href="/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women"</a>.)</p><p></p><p class="headingAnchor" id="H765506878"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113098.html" rel="external">"Society guideline links: Menopause"</a>.)</p><p class="headingAnchor" id="H5292945"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15488.html" rel="external">"Patient education: Menopause (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/2185.html" rel="external">"Patient education: Menopause (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/2158.html" rel="external">"Patient education: Menopausal hormone therapy (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/2167.html" rel="external">"Patient education: Non-estrogen treatments for menopausal symptoms (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H595401618"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Estrogen preparations</strong> – Estrogen is available in many forms: transdermal, oral, topical gels and lotions, intravaginal creams and tablets, and vaginal rings  (<a class="graphic graphic_table graphicRef78136" href="/d/graphic/78136.html" rel="external">table 1</a>). In some countries, estrogen can also be given as a subcutaneous implant All types and routes of estrogen are equally effective for hot flashes, but transdermal preparations are associated with a lower risk of venous thromboembolism and stroke. (See <a class="local">'Estrogen preparations'</a> above and  <a class="medical medical_review" href="/d/html/7450.html" rel="external">"Treatment of menopausal symptoms with hormone therapy", section on 'Route'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Progestin preparations</strong> – Endometrial hyperplasia and cancer can occur after as little as six months of unopposed estrogen therapy; as a result, a progestin should be added in women who have not had a hysterectomy. Women who have undergone hysterectomy should not receive a progestin. (See <a class="local">'Progestin preparations'</a> above and  <a class="medical medical_review" href="/d/html/7450.html" rel="external">"Treatment of menopausal symptoms with hormone therapy", section on 'Progestins'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intolerance to standard oral progestins</strong> – For women unable to tolerate standard oral progestins, alternative approaches include a levonorgestrel-releasing intrauterine system (LNG-IUS; its use is off-label in the United States) or the combination conjugated estrogen-bazedoxifene regimen. The approach to women with progestin intolerance is reviewed separately. (See <a class="local">'Tissue selective estrogen complexes (TSECs)'</a> above and <a class="local">'Levonorgestrel-releasing intrauterine device'</a> above and  <a class="medical medical_review" href="/d/html/7450.html" rel="external">"Treatment of menopausal symptoms with hormone therapy", section on 'Side effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other hormone preparations</strong> – <a class="drug drug_general" data-topicid="129317" href="/d/drug information/129317.html" rel="external">Tibolone</a>, a drug that has been widely used in Europe and other countries for many years for hot flashes, is a synthetic steroid whose metabolites have estrogenic, androgenic, and progestogenic properties. It is <strong>not</strong> available in the United States. Tibolone reduces vasomotor symptoms (although less so than estrogen), improves bone density, and may have a modest effect on symptoms of sexual dysfunction. On the other hand, tibolone increases the risk of recurrence in women with a history of breast cancer, and it may increase the risk of stroke in women over age 60. (See <a class="local">'Other hormone preparations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing and administration </strong>– The practical aspects and recommendations for managing menopausal symptoms with hormone therapy are reviewed separately. (See  <a class="medical medical_review" href="/d/html/7450.html" rel="external">"Treatment of menopausal symptoms with hormone therapy"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Baker VL. Alternatives to oral estrogen replacement. Transdermal patches, percutaneous gels, vaginal creams and rings, implants, other methods of delivery. Obstet Gynecol Clin North Am 1994; 21:271.</a></li><li><a class="nounderline abstract_t">Shephard BD. Low- vs high-dose estradiol vaginal ring in treatment of sexual difficulties. JAMA 2007; 297:2076; author reply 2076.</a></li><li><a class="nounderline abstract_t">Chetkowski RJ, Meldrum DR, Steingold KA, et al. Biologic effects of transdermal estradiol. N Engl J Med 1986; 314:1615.</a></li><li><a class="nounderline abstract_t">Walsh BW, Schiff I, Rosner B, et al. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991; 325:1196.</a></li><li><a class="nounderline abstract_t">Van Erpecum KJ, Van Berge Henegouwen GP, Verschoor L, et al. Different hepatobiliary effects of oral and transdermal estradiol in postmenopausal women. Gastroenterology 1991; 100:482.</a></li><li><a class="nounderline abstract_t">Stevenson JC, Cust MP, Gangar KF, et al. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet 1990; 336:265.</a></li><li><a class="nounderline abstract_t">Pang SC, Greendale GA, Cedars MI, et al. Long-term effects of transdermal estradiol with and without medroxyprogesterone acetate. Fertil Steril 1993; 59:76.</a></li><li><a class="nounderline abstract_t">Jurgens RW Jr, Downey LJ, Abernethy WD, et al. A comparison of circulating hormone levels in postmenopausal women receiving hormone replacement therapy. Am J Obstet Gynecol 1992; 167:459.</a></li><li><a class="nounderline abstract_t">O'Connell MB. Pharmacokinetic and pharmacologic variation between different estrogen products. J Clin Pharmacol 1995; 35:18S.</a></li><li><a class="nounderline abstract_t">Mashchak CA, Lobo RA, Dozono-Takano R, et al. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol 1982; 144:511.</a></li><li><a class="nounderline abstract_t">Ettinger B, Ensrud KE, Wallace R, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol 2004; 104:443.</a></li><li class="breakAll">Pharmaceutical Approvals Monthly June 2004; 9:18.</li><li><a class="nounderline abstract_t">Simon JA, ESTRASORB Study Group. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms. Menopause 2006; 13:222.</a></li><li><a class="nounderline abstract_t">F-D-C Reports, Inc. "The Pink Sheet" 2004; 66:18.</a></li><li><a class="nounderline abstract_t">Archer DF, EstroGel Study Group. Percutaneous 17beta-estradiol gel for the treatment of vasomotor symptoms in postmenopausal women. Menopause 2003; 10:516.</a></li><li><a class="nounderline abstract_t">Hedrick RE, Ackerman RT, Koltun WD, et al. Transdermal estradiol gel 0.1% for the treatment of vasomotor symptoms in postmenopausal women. Menopause 2009; 16:132.</a></li><li class="breakAll">https://www.centerwatch.com/drug-information/fda-approved-drugs/drug/939/elestrin-estradiol-gel (Accessed on October 29, 2014).</li><li class="breakAll">The Medical Letter 2007; 49:69.</li><li><a class="nounderline abstract_t">Buster JE, Koltun WD, Pascual ML, et al. Low-dose estradiol spray to treat vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2008; 111:1343.</a></li><li class="breakAll">US Food and Drug Administration. Evamist (estradiol transdermal spray): Drug Safety Communication - Unintended Exposure of Children and Pets to Topical Estrogen http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm220548.htm (Accessed on September 21, 2010).</li><li><a class="nounderline abstract_t">Prestwood KM, Kenny AM, Kleppinger A, Kulldorff M. Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. JAMA 2003; 290:1042.</a></li><li><a class="nounderline abstract_t">Speroff L. Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms. Obstet Gynecol 2003; 102:823.</a></li><li><a class="nounderline abstract_t">North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause 2012; 19:257.</a></li><li><a class="nounderline abstract_t">ACOG Committee on Gynecologic Practice. ACOG Committee Opinion #322: Compounded bioidentical hormones. Obstet Gynecol 2005; 106:1139.</a></li><li><a class="nounderline abstract_t">Santoro N, Braunstein GD, Butts CL, et al. Compounded Bioidentical Hormones in Endocrinology Practice: An Endocrine Society Scientific Statement. J Clin Endocrinol Metab 2016; 101:1318.</a></li><li><a class="nounderline abstract_t">Shoham Z, Kopernik G. Tools for making correct decisions regarding hormone therapy. part I: background and drugs. Fertil Steril 2004; 81:1447.</a></li><li><a class="nounderline abstract_t">Clisham PR, Cedars MI, Greendale G, et al. Long-term transdermal estradiol therapy: effects on endometrial histology and bleeding patterns. Obstet Gynecol 1992; 79:196.</a></li><li><a class="nounderline abstract_t">Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995; 273:199.</a></li><li><a class="nounderline abstract_t">Gillet JY, Andre G, Faguer B, et al. Induction of amenorrhea during hormone replacement therapy: optimal micronized progesterone dose. A multicenter study. Maturitas 1994; 19:103.</a></li><li><a class="nounderline abstract_t">Hargrove JT, Maxson WS, Wentz AC, Burnett LS. Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone. Obstet Gynecol 1989; 73:606.</a></li><li><a class="nounderline abstract_t">Moorjani S, Dupont A, Labrie F, et al. Changes in plasma lipoprotein and apolipoprotein composition in relation to oral versus percutaneous administration of estrogen alone or in cyclic association with utrogestan in menopausal women. J Clin Endocrinol Metab 1991; 73:373.</a></li><li><a class="nounderline abstract_t">Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med 2014; 161:249.</a></li><li><a class="nounderline abstract_t">Stute P, Neulen J, Wildt L. The impact of micronized progesterone on the endometrium: a systematic review. Climacteric 2016; 19:316.</a></li><li><a class="nounderline abstract_t">Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1996; 275:370.</a></li><li><a class="nounderline abstract_t">de Ziegler D, Ferriani R, Moraes LA, Bulletti C. Vaginal progesterone in menopause: Crinone 4% in cyclical and constant combined regimens. Hum Reprod 2000; 15 Suppl 1:149.</a></li><li><a class="nounderline abstract_t">Cicinelli E, de Ziegler D, Galantino P, et al. Twice-weekly transdermal estradiol and vaginal progesterone as continuous combined hormone replacement therapy in postmenopausal women: a 1-year prospective study. Am J Obstet Gynecol 2002; 187:556.</a></li><li><a class="nounderline abstract_t">Long ME, Faubion SS, MacLaughlin KL, et al. Contraception and hormonal management in the perimenopause. J Womens Health (Larchmt) 2015; 24:3.</a></li><li><a class="nounderline abstract_t">Varila E, Wahlström T, Rauramo I. A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. Fertil Steril 2001; 76:969.</a></li><li><a class="nounderline abstract_t">Wan YL, Holland C. The efficacy of levonorgestrel intrauterine systems for endometrial protection: A systematic review. Climacteric 2011; 14:622.</a></li><li><a class="nounderline abstract_t">Somboonporn W, Panna S, Temtanakitpaisan T, et al. Effects of the levonorgestrel-releasing intrauterine system plus estrogen therapy in perimenopausal and postmenopausal women: systematic review and meta-analysis. Menopause 2011; 18:1060.</a></li><li><a class="nounderline abstract_t">Wildemeersch D, Janssens D, Schacht E, et al. Intrauterine levonorgestrel delivered by a frameless system, combined with systemic estrogen: acceptability and endometrial safety after 3 years of use in peri- and postmenopausal women. Gynecol Endocrinol 2005; 20:336.</a></li><li><a class="nounderline abstract_t">Wildemeersch D, Pylyser K, De Wever N, et al. Endometrial safety after 5 years of continuous combined transdermal estrogen and intrauterine levonorgestrel delivery for postmenopausal hormone substitution. Maturitas 2007; 57:205.</a></li><li><a class="nounderline abstract_t">Lyytinen HK, Dyba T, Ylikorkala O, Pukkala EI. A case-control study on hormone therapy as a risk factor for breast cancer in Finland: Intrauterine system carries a risk as well. Int J Cancer 2010; 126:483.</a></li><li><a class="nounderline abstract_t">Ettinger B, Selby J, Citron JT, et al. Cyclic hormone replacement therapy using quarterly progestin. Obstet Gynecol 1994; 83:693.</a></li><li><a class="nounderline abstract_t">Hirvonen E, Salmi T, Puolakka J, et al. Can progestin be limited to every third month only in postmenopausal women taking estrogen? Maturitas 1995; 21:39.</a></li><li><a class="nounderline abstract_t">Cerin A, Heldaas K, Moeller B. Adverse endometrial effects of long-cycle estrogen and progestogen replacement therapy. The Scandinavian LongCycle Study Group. N Engl J Med 1996; 334:668.</a></li><li><a class="nounderline abstract_t">Archer DF, Thorneycroft IH, Foegh M, et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 2005; 12:716.</a></li><li><a class="nounderline abstract_t">Estradiol/Progesterone (Bijuva) for Menopausal Vasomotor Symptoms. JAMA 2019; 322:1206.</a></li><li><a class="nounderline abstract_t">Lobo RA, Archer DF, Kagan R, et al. A 17β-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial. Obstet Gynecol 2018; 132:161.</a></li><li><a class="nounderline abstract_t">Black DR, Minkin MJ, Graham S, et al. Effects of combined 17β-estradiol and progesterone on weight and blood pressure in postmenopausal women of the REPLENISH trial. Menopause 2020; 28:32.</a></li><li><a class="nounderline abstract_t">Archer DF, Furst K, Tipping D, et al. A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group. Obstet Gynecol 1999; 94:498.</a></li><li><a class="nounderline abstract_t">Formoso G, Perrone E, Maltoni S, et al. Short-term and long-term effects of tibolone in postmenopausal women. Cochrane Database Syst Rev 2016; 10:CD008536.</a></li><li><a class="nounderline abstract_t">Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women. N Engl J Med 2008; 359:697.</a></li><li><a class="nounderline abstract_t">Banks E, Reeves G, Beral V, et al. Hormone replacement therapy and false positive recall in the Million Women Study: patterns of use, hormonal constituents and consistency of effect. Breast Cancer Res 2006; 8:R8.</a></li><li><a class="nounderline abstract_t">Román M, Sakshaug S, Graff-Iversen S, et al. Postmenopausal hormone therapy and the risk of breast cancer in Norway. Int J Cancer 2016; 138:584.</a></li><li><a class="nounderline abstract_t">Kenemans P, Bundred NJ, Foidart JM, et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol 2009; 10:135.</a></li><li><a class="nounderline abstract_t">Modelska K, Cummings S. Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab 2002; 87:16.</a></li><li><a class="nounderline abstract_t">Berning B, van Kuijk C, Bennink HJ, Fauser BC. Absent correlation between vaginal bleeding and oestradiol levels or endometrial morphology during tibolone use in early postmenopausal women. Maturitas 2000; 35:81.</a></li><li><a class="nounderline abstract_t">Archer DF, Hendrix S, Gallagher JC, et al. Endometrial effects of tibolone. J Clin Endocrinol Metab 2007; 92:911.</a></li><li><a class="nounderline abstract_t">Beral V, Bull D, Reeves G, Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005; 365:1543.</a></li></ol></div><div id="topicVersionRevision">Topic 7446 Version 44.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7936545" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Alternatives to oral estrogen replacement. Transdermal patches, percutaneous gels, vaginal creams and rings, implants, other methods of delivery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17507340" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Low- vs high-dose estradiol vaginal ring in treatment of sexual difficulties.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3012339" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Biologic effects of transdermal estradiol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1922206" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1898652" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Different hepatobiliary effects of oral and transdermal estradiol in postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1973969" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8419226" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Long-term effects of transdermal estradiol with and without medroxyprogesterone acetate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1497051" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A comparison of circulating hormone levels in postmenopausal women receiving hormone replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8530713" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Pharmacokinetic and pharmacologic variation between different estrogen products.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6291391" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Comparison of pharmacodynamic properties of various estrogen formulations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15339752" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15339752" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16645536" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : F-D-C Reports, Inc</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14627859" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Percutaneous 17beta-estradiol gel for the treatment of vasomotor symptoms in postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18971794" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Transdermal estradiol gel 0.1% for the treatment of vasomotor symptoms in postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18971794" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Transdermal estradiol gel 0.1% for the treatment of vasomotor symptoms in postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18971794" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Transdermal estradiol gel 0.1% for the treatment of vasomotor symptoms in postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18515518" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Low-dose estradiol spray to treat vasomotor symptoms: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18515518" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Low-dose estradiol spray to treat vasomotor symptoms: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12941676" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14551014" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22367731" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The 2012 hormone therapy position statement of: The North American Menopause Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16260546" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : ACOG Committee Opinion #322: Compounded bioidentical hormones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27032319" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Compounded Bioidentical Hormones in Endocrinology Practice: An Endocrine Society Scientific Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15193460" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Tools for making correct decisions regarding hormone therapy. part I: background and drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1731285" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Long-term transdermal estradiol therapy: effects on endometrial histology and bleeding patterns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7807658" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7968643" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Induction of amenorrhea during hormone replacement therapy: optimal micronized progesterone dose. A multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2538787" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1649840" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Changes in plasma lipoprotein and apolipoprotein composition in relation to oral versus percutaneous administration of estrogen alone or in cyclic association with utrogestan in menopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25069991" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27277331" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The impact of micronized progesterone on the endometrium: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8569016" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10928426" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Vaginal progesterone in menopause: Crinone 4% in cyclical and constant combined regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12237627" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Twice-weekly transdermal estradiol and vaginal progesterone as continuous combined hormone replacement therapy in postmenopausal women: a 1-year prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24773233" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Contraception and hormonal management in the perimenopause.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11704119" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22017273" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The efficacy of levonorgestrel intrauterine systems for endometrial protection: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21720280" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Effects of the levonorgestrel-releasing intrauterine system plus estrogen therapy in perimenopausal and postmenopausal women: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16019384" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Intrauterine levonorgestrel delivered by a frameless system, combined with systemic estrogen: acceptability and endometrial safety after 3 years of use in peri- and postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17227699" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Endometrial safety after 5 years of continuous combined transdermal estrogen and intrauterine levonorgestrel delivery for postmenopausal hormone substitution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19588504" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A case-control study on hormone therapy as a risk factor for breast cancer in Finland: Intrauterine system carries a risk as well.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8164927" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Cyclic hormone replacement therapy using quarterly progestin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7731382" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Can progestin be limited to every third month only in postmenopausal women taking estrogen?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8592546" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Adverse endometrial effects of long-cycle estrogen and progestogen replacement therapy. The Scandinavian LongCycle Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16278615" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31550026" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Estradiol/Progesterone (Bijuva) for Menopausal Vasomotor Symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29889748" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A 17β-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32932401" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Effects of combined 17β-estradiol and progesterone on weight and blood pressure in postmenopausal women of the REPLENISH trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10511348" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27733017" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Short-term and long-term effects of tibolone in postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18703472" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The effects of tibolone in older postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16417651" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Hormone replacement therapy and false positive recall in the Million Women Study: patterns of use, hormonal constituents and consistency of effect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26289549" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Postmenopausal hormone therapy and the risk of breast cancer in Norway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19167925" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11788614" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Tibolone for postmenopausal women: systematic review of randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10802404" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Absent correlation between vaginal bleeding and oestradiol levels or endometrial morphology during tibolone use in early postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17192288" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Endometrial effects of tibolone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15866308" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Endometrial cancer and hormone-replacement therapy in the Million Women Study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
